{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:27Z","timestamp":1787071047556,"version":"build-2736575974"},"reference-count":179,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Spinal muscular atrophy is a devastating motor neuron disease characterized by severe cases of fatal muscle weakness. It is one of the most common genetic causes of mortality among infants aged less than 2 years. Biomarker research is currently receiving more attention, and new candidate biomarkers are constantly being discovered. This review initially discusses the evaluation methods commonly used in clinical practice while briefly outlining their respective pros and cons. We also describe recent advancements in research and the clinical significance of molecular biomarkers for spinal muscular atrophy, which are classified as either specific or non-specific biomarkers. This review provides new insights into the pathogenesis of spinal muscular atrophy, the mechanism of biomarkers in response to drug-modified therapies, the selection of biomarker candidates, and would promote the development of future research. Furthermore, the successful utilization of biomarkers may facilitate the implementation of gene-targeting treatments for patients with spinal muscular atrophy.<\/jats:p>","DOI":"10.4103\/nrr.nrr-d-24-00067","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:05:49Z","timestamp":1719475549000},"page":"1849-1863","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Insights into spinal muscular atrophy from molecular biomarkers"],"prefix":"10.4103","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5983-6762","authenticated-orcid":false,"given":"Xiaodong","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"College of Pharmacy, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiandeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"College of Pharmacy, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"College of Pharmacy, Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-3326","authenticated-orcid":false,"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"R1-20260426","doi-asserted-by":"crossref","first-page":"104870","DOI":"10.1016\/j.nbd.2020.104870","article-title":"Glial cells involvement in spinal muscular atrophy: Could SMA be a neuroinflammatory disease?","volume":"140","author":"Abati","year":"2020","journal-title":"Neurobiol Dis"},{"key":"R2-20260426","doi-asserted-by":"crossref","first-page":"e68054","DOI":"10.7554\/eLife.68054","article-title":"SMA-miRs (miR-181a-5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples","volume":"10","author":"Abiusi","year":"2021","journal-title":"Elife"},{"key":"R3-20260426","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","article-title":"CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia","volume":"12","author":"Abu-Rumeileh","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"R4-20260426","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.4103\/1673-5374.386406","article-title":"Amyloid-beta and tau protein beyond Alzheimer\u2019s disease","volume":"19","author":"Abyadeh","year":"2024","journal-title":"Neural Regen Res"},{"key":"R5-20260426","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12031-010-9422-1","article-title":"Alpha-synuclein loss in spinal muscular atrophy","volume":"43","author":"Acsadi","year":"2011","journal-title":"J Mol Neurosci"},{"key":"R6-20260426","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4103\/1673-5374.385293","article-title":"Anti-aquaporin-4 antibody (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in the cerebrospinal fluid","volume":"19","author":"Akaishi","year":"2024","journal-title":"Neural Regen Res"},{"key":"R7-20260426","first-page":"65","article-title":"Evaluation of the therapeutic efficacy and tolerability of current drug treatments on the clinical outcomes of paediatric spinal muscular atrophy type 1: a systematic review","volume":"48","author":"Al-Taie","year":"2023","journal-title":"Paediatr Respir Rev"},{"key":"R8-20260426","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/glia.24153","article-title":"Viral mediated knockdown of GATA6 in SMA iPSC-derived astrocytes prevents motor neuron loss and microglial activation","volume":"70","author":"Allison","year":"2022","journal-title":"Glia"},{"key":"R9-20260426","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.4049\/jimmunol.149.7.2358","article-title":"Production of hemolymphopoietic cytokines (IL-6, IL-8, colony-stimulating factors) by normal human astrocytes in response to IL-1 beta and tumor necrosis factor-alpha","volume":"149","author":"Aloisi","year":"1992","journal-title":"J Immunol"},{"key":"R10-20260426","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology"},{"key":"R11-20260426","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mus.26995","article-title":"Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy","volume":"62","author":"Alves","year":"2020","journal-title":"Muscle Nerve"},{"key":"R12-20260426","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.10.011","article-title":"Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: a case series","volume":"23","author":"Alves","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R13-20260426","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jphs.2020.09.001","article-title":"Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy","volume":"144","author":"Ando","year":"2020","journal-title":"J Pharmacol Sci"},{"key":"R14-20260426","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.bbrc.2014.09.087","article-title":"A novel evaluation method of survival motor neuron protein as a biomarker of spinal muscular atrophy by imaging flow cytometry","volume":"453","author":"Arakawa","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"R15-20260426","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41582-020-0348-0","article-title":"An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders","volume":"16","author":"Ashton","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R16-20260426","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.3390\/jcm12155060","article-title":"Molecular biomarkers for the diagnosis, prognosis, and pharmacodynamics of spinal muscular atrophy","volume":"12","author":"Babi\u0107","year":"2023","journal-title":"J Clin Med"},{"key":"R17-20260426","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20260426","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nri.2016.123","article-title":"Cytokine networks in neuroinflammation","volume":"17","author":"Becher","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R19-20260426","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41434-022-00341-6","article-title":"Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study","volume":"30","author":"Bitetti","year":"2023","journal-title":"Gene Ther"},{"key":"R20-20260426","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/biomedicines8020021","article-title":"Circulating MyomiRs as potential biomarkers to monitor response to nusinersen in pediatric SMA patients","volume":"8","author":"Bonanno","year":"2020","journal-title":"Biomedicines"},{"key":"R21-20260426","doi-asserted-by":"crossref","first-page":"982760","DOI":"10.3389\/fncel.2022.982760","article-title":"Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment","volume":"16","author":"Bonanno","year":"2022","journal-title":"Front Cell Neurosci"},{"key":"R22-20260426","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.20836","article-title":"In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate","volume":"59","author":"Brichta","year":"2006","journal-title":"Ann Neurol"},{"key":"R23-20260426","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4103\/1673-5374.382256","article-title":"Activation of cerebral Ras-related C3 botulinum toxin substrate (Rac) 1 promotes post-ischemic stroke functional recovery in aged mice","volume":"19","author":"Bu","year":"2024","journal-title":"Neural Regen Res"},{"key":"R24-20260426","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/hmg\/7.12.1927","article-title":"The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy","volume":"7","author":"Burlet","year":"1998","journal-title":"Hum Mol Genet"},{"key":"R25-20260426","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nn1715","article-title":"Control of microglial neurotoxicity by the fractalkine receptor","volume":"9","author":"Cardona","year":"2006","journal-title":"Nat Neurosci"},{"key":"R26-20260426","doi-asserted-by":"crossref","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep Med"},{"key":"R27-20260426","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1515\/cclm-2020-1030","article-title":"Reference values for plasma neurofilament light chain (NfL) in healthy Chinese","volume":"59","author":"Chen","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"R28-20260426","doi-asserted-by":"crossref","first-page":"1756286420979954","DOI":"10.1177\/1756286420979954","article-title":"Circulating microRNAs as potential biomarkers and therapeutic targets in spinal muscular atrophy","volume":"13","author":"Chen","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"R29-20260426","doi-asserted-by":"crossref","first-page":"e50848","DOI":"10.7554\/eLife.50848","article-title":"Multifaceted roles of microRNAs: From motor neuron generation in embryos to degeneration in spinal muscular atrophy","volume":"8","author":"Chen","year":"2019","journal-title":"Elife"},{"key":"R30-20260426","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2023.03.005","article-title":"MiR34 contributes to spinal muscular atrophy and AAV9-mediated delivery of MiR34a ameliorates the motor deficits in SMA mice","volume":"32","author":"Chen","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"R31-20260426","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"R32-20260426","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: an interim analysis from the JEWELFISH Study","volume":"12","author":"Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"key":"R33-20260426","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/hmg\/11.12.1439","article-title":"Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model","volume":"11","author":"Cifuentes-Diaz","year":"2002","journal-title":"Hum Mol Genet"},{"key":"R34-20260426","doi-asserted-by":"crossref","first-page":"e0139950","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS One"},{"key":"R35-20260426","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/pharmaceutics15010170","article-title":"Identification of novel CSF-derived miRNAs in treated paediatric onset spinal muscular atrophy: an exploratory study","volume":"15","author":"D\u2019Silva","year":"2023","journal-title":"Pharmaceutics"},{"key":"R36-20260426","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"R37-20260426","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4103\/NRR.NRR-D-23-01677","article-title":"A systematic review of salivary biomarkers in Parkinson\u2019s disease","volume":"19","author":"De Bartolo","year":"2024","journal-title":"Neural Regen Res"},{"key":"R38-20260426","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"R39-20260426","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/acn3.51625","article-title":"Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months","volume":"9","author":"De Wel","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R40-20260426","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol"},{"key":"R41-20260426","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acn3.423","article-title":"New insights into SMA pathogenesis: immune dysfunction and neuroinflammation","volume":"4","author":"Deguise","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"R42-20260426","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/metabo11040206","article-title":"Spinal muscular atrophy after nusinersen therapy: improved physiology in pediatric patients with no significant change in urine, serum, and liquor 1H-NMR metabolomes in comparison to an age-matched, healthy cohort","volume":"11","author":"Deutsch","year":"2021","journal-title":"Metabolites"},{"key":"R43-20260426","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1515\/cclm-2022-0767","article-title":"The chitinases as biomarkers in immune-mediate diseases","volume":"61","author":"Di Francesco","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"R44-20260426","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol"},{"key":"R45-20260426","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"R46-20260426","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.4049\/jimmunol.160.4.1944","article-title":"Cytokine regulation of human microglial cell IL-8 production","volume":"160","author":"Ehrlich","year":"1998","journal-title":"J Immunol"},{"key":"R47-20260426","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/acn3.51377","article-title":"Increased systemic HSP70B levels in spinal muscular atrophy infants","volume":"8","author":"Eichelberger","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R48-20260426","doi-asserted-by":"crossref","first-page":"102037","DOI":"10.1016\/j.arr.2023.102037","article-title":"Neurofilaments - small proteins of physiological significance and predictive power for future neurodegeneration and cognitive decline across the life span","volume":"90","author":"Elmers","year":"2023","journal-title":"Ageing Res Rev"},{"key":"R49-20260426","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00018-023-04885-7","article-title":"Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study","volume":"80","author":"Faravelli","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"R50-20260426","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"R51-20260426","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acn3.51562","article-title":"Scientific rationale for a higher dose of nusinersen","volume":"9","author":"Finkel","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R52-20260426","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s13023-021-01961-8","article-title":"Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy","volume":"16","author":"Freigang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R53-20260426","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R54-20260426","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/acn3.51645","article-title":"Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy","volume":"9","author":"Freigang","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R55-20260426","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R56-20260426","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.nmd.2021.12.005","article-title":"Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis","volume":"32","author":"Gavriilaki","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"R57-20260426","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3389\/fneur.2019.00735","article-title":"Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen","volume":"10","author":"Gingele","year":"2019","journal-title":"Front Neurol"},{"key":"R58-20260426","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"R59-20260426","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol"},{"key":"R60-20260426","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/PEP.0b013e3182351f04","article-title":"Validation of the Children\u2019s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)","volume":"23","author":"Glanzman","year":"2011","journal-title":"Pediatr Phys Ther"},{"key":"R61-20260426","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3233\/JND-230054","article-title":"Identifying biomarkers of spinal muscular atrophy for further development","volume":"10","author":"Glascock","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"R62-20260426","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13024-023-00605-8","article-title":"Plasma phospho-tau in Alzheimer\u2019s disease: towards diagnostic and therapeutic trial applications","volume":"18","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Mol Neurodegener"},{"key":"R63-20260426","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/acn3.51114","article-title":"CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis","volume":"7","author":"Gray","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"R64-20260426","first-page":"1952","article-title":"Neurodevelopmental defects as a primer of neurodegeneration: lessons from spinal muscular atrophy and Huntington\u2019s disease","volume":"18","author":"Grice","year":"2023","journal-title":"Neural Regen Res"},{"key":"R65-20260426","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R66-20260426","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","article-title":"Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy","volume":"27","author":"Groen","year":"2018","journal-title":"Hum Mol Genet"},{"key":"R67-20260426","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol Med"},{"key":"R68-20260426","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/jnnp-2020-322949","article-title":"Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)","volume":"91","author":"Hashizume","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R69-20260426","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.4103\/1673-5374.389357","article-title":"Circulating proteomic biomarkers for diagnosing sporadic amyotrophic lateral sclerosis: a cross-sectional study","volume":"19","author":"He","year":"2024","journal-title":"Neural Regen Res"},{"key":"R70-20260426","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/cclm-2015-0253","article-title":"Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity","volume":"54","author":"Hegen","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"R71-20260426","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","article-title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system","volume":"32","author":"Hol","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"R72-20260426","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.3390\/ijms23137307","article-title":"Tau as a biomarker of neurodegeneration","volume":"23","author":"Holper","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R73-20260426","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"R74-20260426","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"R75-20260426","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/mus.27212","article-title":"Is cerebrospinal fluid amyloid-\u03b242 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?","volume":"63","author":"Introna","year":"2021","journal-title":"Muscle Nerve"},{"key":"R76-20260426","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/JND-170209","article-title":"SMN blood levels in a porcine model of spinal muscular atrophy","volume":"4","author":"Iyer","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"R77-20260426","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1515\/cclm-2021-0804","article-title":"Reference values for plasma neurofilament light chain in healthy Chinese children","volume":"60","author":"Jin","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"R78-20260426","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.1111\/jcmm.16802","article-title":"Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen","volume":"25","author":"Johannsen","year":"2021","journal-title":"J Cell Mol Med"},{"key":"R79-20260426","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front Neurol"},{"key":"R80-20260426","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14953","article-title":"Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy","volume":"153","author":"Kessler","year":"2020","journal-title":"J Neurochem"},{"key":"R81-20260426","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R82-20260426","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","article-title":"Serum neurofilament light levels in normal aging and their association with morphologic brain changes","volume":"11","author":"Khalil","year":"2020","journal-title":"Nat Commun"},{"key":"R83-20260426","doi-asserted-by":"crossref","first-page":"n1486","DOI":"10.1136\/bmj.n1486","article-title":"Investigating raised creatine kinase","volume":"373","author":"Kim","year":"2021","journal-title":"BMJ"},{"key":"R84-20260426","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2022.09.008","article-title":"Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy","volume":"45","author":"Kobayashi","year":"2023","journal-title":"Brain Dev"},{"key":"R85-20260426","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"R86-20260426","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/diagnostics11091522","article-title":"CSF diagnostics: a potentially valuable tool in neurodegenerative and inflammatory disorders involving motor neurons: a review","volume":"11","author":"Krause","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R87-20260426","doi-asserted-by":"crossref","first-page":"e22948","DOI":"10.1002\/jcla.22948","article-title":"Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels","volume":"33","author":"Ku\u0161nierov\u00e1","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R88-20260426","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/biom12020329","article-title":"Update on CSF biomarkers in Parkinson\u2019s disease","volume":"12","author":"Kwon","year":"2022","journal-title":"Biomolecules"},{"key":"R89-20260426","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/brainsci10010056","article-title":"Neurofilaments: the C-reactive protein of neurology","volume":"10","author":"Lambertsen","year":"2020","journal-title":"Brain Sci"},{"key":"R90-20260426","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.3390\/ijms21082911","article-title":"A\u03b21\u201342 and tau as potential biomarkers for diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"21","author":"Lanznaster","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R91-20260426","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1007\/s00415-023-11787-y","article-title":"Biomarkers in 5q-associated spinal muscular atrophy-a narrative review","volume":"270","author":"Lapp","year":"2023","journal-title":"J Neurol"},{"key":"R92-20260426","doi-asserted-by":"crossref","first-page":"e2997","DOI":"10.1002\/brb3.2997","article-title":"Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: a pilot study","volume":"13","author":"Li","year":"2023","journal-title":"Brain Behav"},{"key":"R93-20260426","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4103\/NRR.NRR-D-24-00109","article-title":"Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends","volume":"19","author":"Li","year":"2024","journal-title":"Neural Regen Res"},{"key":"R94-20260426","doi-asserted-by":"crossref","first-page":"e15457","DOI":"10.1371\/journal.pone.0015457","article-title":"Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy","volume":"5","author":"Ling","year":"2010","journal-title":"PLoS One"},{"key":"R95-20260426","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/1673-5374.344839","article-title":"Diffusion tensor imaging reveals brain structure changes in dogs after spinal cord injury","volume":"18","author":"Liu","year":"2023","journal-title":"Neural Regen Res"},{"key":"R96-20260426","doi-asserted-by":"crossref","first-page":"e1205","DOI":"10.1212\/WNL.0000000000007097","article-title":"Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy","volume":"92","author":"Lombardi","year":"2019","journal-title":"Neurology"},{"key":"R97-20260426","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"R98-20260426","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1111\/ijlh.13392","article-title":"Unusual inclusions in cerebrospinal fluid macrophages of spinal muscular atrophy patients treated with nusinersen","volume":"43","author":"Machacek","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"R99-20260426","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/ene.15382","article-title":"Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients","volume":"29","author":"Magen","year":"2022","journal-title":"Eur J Neurol"},{"key":"R100-20260426","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1523\/JNEUROSCI.3472-16.2017","article-title":"Decreased motor neuron support by SMA astrocytes due to diminished MCP1 secretion","volume":"37","author":"Martin","year":"2017","journal-title":"J Neurosci"},{"key":"R101-20260426","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"R102-20260426","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.3390\/ijms22136966","article-title":"Chitinases and chitinase-like proteins as therapeutic targets in inflammatory diseases, with a special focus on inflammatory bowel diseases","volume":"22","author":"Mazur","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R103-20260426","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mus.25430","article-title":"Revised upper limb module for spinal muscular atrophy: development of a new module","volume":"55","author":"Mazzone","year":"2017","journal-title":"Muscle Nerve"},{"key":"R104-20260426","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1373\/clinchem.2017.278267","article-title":"Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data","volume":"63","author":"McCudden","year":"2017","journal-title":"Clin Chem"},{"key":"R105-20260426","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/biomedicines11051254","article-title":"Identification of novel biomarkers of spinal muscular atrophy and therapeutic response by proteomic and metabolomic profiling of human biological fluid samples","volume":"11","author":"Meneri","year":"2023","journal-title":"Biomedicines"},{"key":"R106-20260426","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy - insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"R107-20260426","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"R108-20260426","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"Mercuri","year":"2023","journal-title":"Eur J Neurol"},{"key":"R109-20260426","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jnc.14574","article-title":"The S100B story: from biomarker to active factor in neural injury","volume":"148","author":"Michetti","year":"2019","journal-title":"J Neurochem"},{"key":"R110-20260426","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.3390\/ijms24119605","article-title":"The S100B protein: a multifaceted pathogenic factor more than a biomarker","volume":"24","author":"Michetti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R111-20260426","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pneurobio.2011.01.005","article-title":"GFAP in health and disease","volume":"93","author":"Middeldorp","year":"2011","journal-title":"Prog Neurobiol"},{"key":"R112-20260426","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40261-021-01071-0","article-title":"Cerebrospinal fluid and clinical profiles in adult type 2-3 spinal muscular atrophy patients treated with nusinersen: an 18-month single-centre experience","volume":"41","author":"Milella","year":"2021","journal-title":"Clin Drug Investig"},{"key":"R113-20260426","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: current status and future directions in treating Alzheimer\u2019s disease","volume":"40","author":"Moussa-Pacha","year":"2020","journal-title":"Med Res Rev"},{"key":"R114-20260426","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/brainsci11030296","article-title":"Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients","volume":"11","author":"M\u00fcschen","year":"2021","journal-title":"Brain Sci"},{"key":"R115-20260426","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1212\/NXG.0000000000000353","article-title":"Impaired kidney structure and function in spinal muscular atrophy","volume":"5","author":"Nery","year":"2019","journal-title":"Neurol Genet"},{"key":"R116-20260426","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/acn3.51449","article-title":"Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children","volume":"8","author":"Nitz","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R117-20260426","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1352458516639384","article-title":"Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis","volume":"23","author":"Novakova","year":"2017","journal-title":"Mult Scler"},{"key":"R118-20260426","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-023-00256-2","article-title":"Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients","volume":"3","author":"Nuzzo","year":"2023","journal-title":"Commun Med (Lond)"},{"key":"R119-20260426","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J Neurol"},{"key":"R120-20260426","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/mus.27731","article-title":"Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy","volume":"66","author":"Orbach","year":"2022","journal-title":"Muscle Nerve"},{"key":"R121-20260426","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.nbd.2009.10.005","article-title":"Inflammation in ALS and SMA: sorting out the good from the evil","volume":"37","author":"Papadimitriou","year":"2010","journal-title":"Neurobiol Dis"},{"key":"R122-20260426","doi-asserted-by":"crossref","first-page":"e24236","DOI":"10.1097\/MD.0000000000024236","article-title":"Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: A case report","volume":"100","author":"Park","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R123-20260426","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1474-4422(19)30405-3","article-title":"Serum neurofilament light chain as a preclinical marker of neurodegeneration","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"R124-20260426","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/phar.2866","article-title":"Efficacy of risdiplam in spinal muscular atrophy: a systematic review and meta-analysis","volume":"44","author":"Pascual-Morena","year":"2024","journal-title":"Pharmacotherapy"},{"key":"R125-20260426","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"R126-20260426","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jnnp.2009.200253","article-title":"Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid","volume":"82","author":"Piepers","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R127-20260426","doi-asserted-by":"crossref","first-page":"11772719211035643","DOI":"10.1177\/11772719211035643","article-title":"Update on biomarkers in spinal muscular atrophy","volume":"16","author":"Pino","year":"2021","journal-title":"Biomark Insights"},{"key":"R128-20260426","doi-asserted-by":"crossref","first-page":"e00447","DOI":"10.1002\/prp2.447","article-title":"Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs","volume":"6","author":"Poirier","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"R129-20260426","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/jir.2012.0132","article-title":"Pediatric reference ranges for proinflammatory and anti-inflammatory cytokines in cerebrospinal fluid and serum by multiplexed immunoassay","volume":"33","author":"Pranzatelli","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"R130-20260426","doi-asserted-by":"crossref","first-page":"S4725","DOI":"10.1212\/WNL.94.15_supplement.4725","article-title":"Effect of Nusinsersen in an Adult SMA Cohort: CSF Biomarkers and RULM (4725)","volume":"94","author":"Quinn","year":"2020","journal-title":"Neurology"},{"key":"R131-20260426","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest"},{"key":"R132-20260426","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"R133-20260426","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","article-title":"Curing SMA: Are we there yet?","volume":"30","author":"Reilly","year":"2023","journal-title":"Gene Ther"},{"key":"R134-20260426","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1212\/NXI.0000000000000749","article-title":"Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis","volume":"7","author":"Reinert","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R135-20260426","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-150081","article-title":"Spinal muscular atrophy biomarker measurements from blood samples in a clinical trial of valproic acid in ambulatory adults","volume":"2","author":"Renusch","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"R136-20260426","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000007926","article-title":"Analysis of creatine kinase activity in 504 patients with proximal spinal muscular atrophy types I-III from the point of view of progression and severity","volume":"39","author":"Rudnik-Sch\u00f6neborn","year":"1998","journal-title":"Eur Neurol"},{"key":"R137-20260426","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s13023-021-02075-x","article-title":"(1)H-NMR-based metabolic profiling identifies non-invasive diagnostic and predictive urinary fingerprints in 5q spinal muscular atrophy","volume":"16","author":"Saffari","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"R138-20260426","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1055\/s-0042-1750719","article-title":"The effect of nusinersen therapy on laboratory parameters of patients with spinal muscular atrophy","volume":"53","author":"Sar\u0131kaya Uzan","year":"2022","journal-title":"Neuropediatrics"},{"key":"R139-20260426","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpn.2022.12.003","article-title":"Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment","volume":"42","author":"Scheijmans","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"R140-20260426","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"R141-20260426","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/ene.15331","article-title":"Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy","volume":"29","author":"Schorling","year":"2022","journal-title":"Eur J Neurol"},{"key":"R142-20260426","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00415-022-11507-y","article-title":"Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis","volume":"270","author":"Sen","year":"2023","journal-title":"J Neurol"},{"key":"R143-20260426","doi-asserted-by":"crossref","first-page":"e14051","DOI":"10.1111\/cns.14051","article-title":"Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen","volume":"30","author":"\u0160imi\u0107","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"R144-20260426","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.3390\/ijms22179207","article-title":"Tau protein interaction partners and their roles in Alzheimer\u2019s disease and other tauopathies","volume":"22","author":"Sinsky","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R145-20260426","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/acn3.51092","article-title":"Whole-blood dysregulation of actin-cytoskeleton pathway in adult spinal muscular atrophy patients","volume":"7","author":"Siranosian","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"R146-20260426","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/hmg\/ddx230","article-title":"Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy","volume":"26","author":"Sison","year":"2017","journal-title":"Hum Mol Genet"},{"key":"R147-20260426","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/jpm10030075","article-title":"The identification of novel biomarkers is required to improve adult SMA patient stratification, Diagnosis and Treatment","volume":"10","author":"Smeriglio","year":"2020","journal-title":"J Pers Med"},{"key":"R148-20260426","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","article-title":"Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression","volume":"89","author":"Steinacker","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R149-20260426","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","article-title":"Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"268","author":"Stolte","year":"2021","journal-title":"J Neurol"},{"key":"R150-20260426","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R151-20260426","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"R152-20260426","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/NEN.0000000000000074","article-title":"Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy","volume":"73","author":"Tarabal","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"R153-20260426","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"key":"R154-20260426","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2019-320442","article-title":"CSF chitinase proteins in amyotrophic lateral sclerosis","volume":"90","author":"Thompson","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R155-20260426","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat Med"},{"key":"R156-20260426","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J Med Genet"},{"key":"R157-20260426","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.3390\/ijms20215397","article-title":"Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen","volume":"20","author":"Totzeck","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R158-20260426","doi-asserted-by":"crossref","first-page":"e0135886","DOI":"10.1371\/journal.pone.0135886","article-title":"Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction","volume":"10","author":"V\u00e5gberg","year":"2015","journal-title":"PLoS One"},{"key":"R159-20260426","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12974-020-01909-y","article-title":"Chitotriosidase, a biomarker of amyotrophic lateral sclerosis, accentuates neurodegeneration in spinal motor neurons through neuroinflammation","volume":"17","author":"Varghese","year":"2020","journal-title":"J Neuroinflammation"},{"key":"R160-20260426","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1111\/ene.15542","article-title":"Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy","volume":"29","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol"},{"key":"R161-20260426","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13311-022-01305-9","article-title":"CSF IL-8 associated with response to gene therapy in a case series of spinal muscular atrophy","volume":"20","author":"Verma","year":"2023","journal-title":"Neurotherapeutics"},{"key":"R162-20260426","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejpn.2013.09.005","article-title":"Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy","volume":"18","author":"Vry","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"R163-20260426","doi-asserted-by":"crossref","first-page":"e0167087","DOI":"10.1371\/journal.pone.0167087","article-title":"A comparative study of SMN protein and mrna in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls","volume":"11","author":"Wadman","year":"2016","journal-title":"PLoS One"},{"key":"R164-20260426","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"R165-20260426","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fneur.2017.00196","article-title":"Serum creatinine distinguishes Duchenne muscular dystrophy from becker muscular dystrophy in patients aged \u2264 3 years: a retrospective study","volume":"8","author":"Wang","year":"2017","journal-title":"Front Neurol"},{"key":"R166-20260426","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","article-title":"A current view on Tau protein phosphorylation in Alzheimer\u2019s disease","volume":"69","author":"Wegmann","year":"2021","journal-title":"Curr Opin Neurobiol"},{"key":"R167-20260426","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/hmg\/ddab365","article-title":"Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples","volume":"31","author":"Welby","year":"2022","journal-title":"Hum Mol Genet"},{"key":"R168-20260426","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2018-320033","article-title":"Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen","volume":"90","author":"Winter","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R169-20260426","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci"},{"key":"R170-20260426","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","article-title":"Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next","volume":"21","author":"Wirth","year":"2020","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"R171-20260426","first-page":"197","article-title":"Neuroinflammation in spinal muscular atrophy","volume":"19","author":"Wood","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"R172-20260426","doi-asserted-by":"crossref","first-page":"1756286419846058","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"R173-20260426","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fneur.2019.01179","article-title":"Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen","volume":"10","author":"Wurster","year":"2019","journal-title":"Front Neurol"},{"key":"R174-20260426","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"key":"R175-20260426","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","article-title":"Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls","volume":"17","author":"Yilmaz","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"R176-20260426","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acn3.51579","article-title":"Response of plasma microRNAs to nusinersen treatment in patients with SMA","volume":"9","author":"Zaharieva","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"R177-20260426","doi-asserted-by":"crossref","first-page":"e0150640","DOI":"10.1371\/journal.pone.0150640","article-title":"SMN protein can be reliably measured in whole blood with an electrochemiluminescence (ECL) immunoassay: implications for clinical trials","volume":"11","author":"Zaworski","year":"2016","journal-title":"PLoS One"},{"key":"R178-20260426","doi-asserted-by":"crossref","first-page":"141856","DOI":"10.1155\/2015\/141856","article-title":"Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy","volume":"2015","author":"Zhang","year":"2015","journal-title":"Dis Markers"},{"key":"R179-20260426","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.3390\/ijms231810878","article-title":"Mitochondrial dysfunction in spinal muscular atrophy","volume":"23","author":"Zilio","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-24-00067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:44Z","timestamp":1787067644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/NRR.NRR-D-24-00067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":179,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/nrr.nrr-d-24-00067","relation":{},"ISSN":["1673-5374","1876-7958"],"issn-type":[{"value":"1673-5374","type":"print"},{"value":"1876-7958","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"2024-01-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}